Your session is about to expire
← Back to Search
Deucravacitinib for Psoriasis (POETYK PSO-LTE Trial)
POETYK PSO-LTE Trial Summary
This trial will study the long-term safety and effectiveness of the drug Deucravacitinib in people who have previously taken it for psoriasis in a different trial.
POETYK PSO-LTE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPOETYK PSO-LTE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 220 Patients • NCT04167462POETYK PSO-LTE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any signs or symptoms of tuberculosis.I am not pregnant, lactating, or breastfeeding.
- Group 1: BMS-986165
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the desired sample size for this clinical trial?
"As of right now, this trial does not have any open slots for new participants. According to the information provided by clinicaltrials.gov, the last time this study was edited was on July 1st, 2022. However, if you are looking for other studies to participate in, there are presently 179 clinical trials actively recruiting participants with psoriasis and 11 studies for BMS-986165 actively recruiting participants."
Are there other instances of BMS-986165 being trialed?
"H-T. Centrum Medyczne Spolka z Ograniczona Odpowiedzialnoscia first studied BMS-986165 in 2018 and, to date, there are 34 completed studies. 11 clinical trials using this medication are ongoing with a large proportion taking place in Stony Brook, New york."
What have been the side effects observed in individuals taking BMS-986165?
"BMS-986165 is in Phase 3 of clinical trials, meaning that there is efficacy data as well as multiple rounds of safety data. Therefore, it received a score of 3 for safety."
Has this research been done before?
"BMS-986165 has been investigated in clinical trials since 2018. The first trial, sponsored by Bristol-Myers Squibb concluded that year and involved 240 patients. Phase 2 approval was granted after the successful completion of this initial study. Currently, 11 ongoing trials are being conducted in 400 locations across 36 countries."
In how many different medical institutions is this research being conducted?
"Local Institution - 0218 in Stony Brook, New york, LCC Medical Research in Miami, Florida, Marietta Dermatology & The Skin cancer Center in Marietta, Georgia are some of the 67 sites running this study."
Are we looking for more participants in this trial at the moment?
"According to the latest information available on clinicaltrials.gov, this trial is no longer recruiting patients. Although the study's last update was on July 1st, 2022, it is not presently looking for any more participants. There are however, 190 other trials that are still enrolling individuals."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger